

The Mechanism of Quinolone Resistance in *Staphylococcus aureus*

Lee, Youngyeong, Jaeyang Kong, Youngha Rhee¹ and Eunhee Kim²

Korea Research Institute of Chemical Technology,
Pharmaceutical Screening Laboratory Daejeon 305-606, Korea

¹Department of Microbiology, College of Natural Sciences,
Chungnam National University, Daejeon 305-764, Korea

²Department of Genetic Engineering,
College of Science and Engineering, Pai-chai University, Daejeon 302-735, Korea

Clinical isolates of 8 ofloxacin resistant *Staphylococcus aureus* (ORSA) were subjected to MIC test, Southern analysis on *gyrA* locus and nucleotide sequence analysis of 290 bp of *gyrA* gene (*gyrA*-290) spanning amino acid 26 to 121 in order to understand the mechanism of quinolone resistance in *Staphylococcus aureus*. ORSAs showed high level resistance against quinolones (8-250 fold increase of MICs) and also significant resistance against β -lactams (2-32 fold increase of MICs). However, ORSAs did not show any change in sensitivity against vancomycin. Southern analysis of ORSAs with *HindIII*, *PstI* and *AluI* revealed RFLPs on *gyrA* locus. In order to further analyze the *gyrA* gene, *gyrA*-290 was amplified by PCR and cloned to pTZ vector. Subsequent nucleic acid sequence analysis of *gyrA*-290 demonstrated a point mutation of C to T resulting amino acid change of Ser-84 to Leu-84 in all 8 ORSA strains. The substitution at 84th amino acid of gyrase A might confer one mechanism of high level quinolone resistance in *Staphylococcus aureus*.

KEY WORDS □ *Staphylococcus aureus*, *gyrA*, quinolone, resistance

Quinolones are fully synthesized *in vitro*, potent antibacterial agents that have been widely used in the treatment of different bacterial infections including methicillin-resistant *Staphylococcus aureus*, a problematic pathogen resistant against varieties of antibiotics (16). Most widely known quinolones are norfloxacin, ofloxacin, ciprofloxacin and sparfloxacin. Quinolone usage is dramatically increasing because of its favorable pharmacokinetic and toxicological profile as well as its wide spectrum and potency (2).

Quinolones are known to inhibit gyrase A, thereby prevent bacterial DNA replication. The DNA gyrase is a topoisomerase which catalyzes the supercoiling of relaxed covalently closed circular DNA, which is coupled with the hydrolysis of ATP (4, 15). Most studies on gyrases are done with *E. coli* (1, 5, 11, 16). Gyrase is composed of 2 different subunits, A and B, which are encoded by *gyrA* and *gyrB* gene respectively. Gyrase A is the target for quinolones whereas gyrase B is that for novobiocin and coumermycin (10).

While the details of the quinolone-DNA-gyrase

interaction are still unequivocal, it seems clear that enzyme-DNA complex is formed and subsequently both strands of DNA are cleaved in the presence of quinolones. This irreversible formation of DNA strand breakage triggers a sequence of events that lead to cell death ultimately (9, 18).

Staphylococcal infections, particularly methicillin resistant ones, are a serious medical problem (3). Unfortunately quinolone resistant *S. aureus* isolates seem to appear. The emergence of quinolone resistant *S. aureus* is of particular concern given that relatively few antimicrobial agents are effective against them (8, 13, 14).

The molecular basis of quinolone resistance in *S. aureus* is not well-understood. There has not yet been a report that quinolone resistance is mediated via plasmid. In *E. coli*, quinolone resistance seems to arise through mutations of gyrase A and, less often, gyrase B (2, 6, 7). In particular, amino acid substitutions near Tyr-122 of gyrase A, the site of DNA attachment, were observed in quinolone resistant *E. coli* strains. However it is worthy of mentioning that most of




Fig. 2. Cloning strategy of *gyrA-290* by PCR amplification.

chromosomal DNA. We routinely programmed the reaction as follows; 1 cycle of step 1 (15 min at 94°C, 1 min at 55°C), 33 cycles of step 2 (1 min at 94°C, 1 min at 55°C, 1 min at 72°C) and 1 cycle of step 3 (1 min at 94°C, 1 min at 55°C, 5 min at 72°C). The amplified product was checked on 1.5% agarose gel and the *gyrA-290* fragments were isolated with electroelutor (Hofer, USA).

Nucleotide Sequence Analysis of *gyrA-290*

The *gyrA-290* fragments amplified by PCR were

phosphorylated and treated with Klenow enzyme (KOSCO, Korea) in order to make blunt ends. pTZ vector (obtained from Genetic Engineering Research Institute) was digested with HincII (KOSCO, Korea) to make blunt ends. Thus, blunt end ligation was performed between the *gyrA-290* and pTZ vector. The cloning scheme is shown in Fig. 2. The cloned *gyrA-290* was subjected to sequence analysis. DNA sequences were determined by dideoxy chain termination method with the DNA sequencing kit (USBC, USA).

RESULTS

Antimicrobial Susceptibilities of *S. aureus*

The MICs of OSSA and ORSA against seven antibiotics were determined (Table 1). ORSAs showed 15-30 fold higher MICs against ofloxacin, 10-60 fold against ciprofloxacin and norfloxacin than those of OSSAs. The resistance of ORSAs against hydrophobic quinolone, sparfloxacin, was most dramatic i.e. 60-250 fold higher MICs than those of OSSAs. In case of cefotaxime and methicillin, which are β -lactams, the MIC of ORSAs was also increased 2-30 fold than those of OSSAs. It is noteworthy that vancomycin was highly effective against ORSAs as well as OSSAs. Among ORSAs, *S. aureus* 17613 was most resistant against three hydrophilic quinolones.

Southern Analysis of *gyrA* gene

The possibility that the nucleotide sequence changes in gyrase A gene, thereby resulting RFLPs in that locus, might be involved in quinolone resistance mechanism was examined. Since we did not have the *gyrA* clone of *S. aureus*, *E. coli gyrA* clone was used to detect restriction fragments of *S. aureus gyrA*. *E. coli gyrA* probe hybridized to *S. aureus gyrA* under the condition described above. However the hybridization signal

Table 1. Antimicrobial agent susceptibility of *S. aureus* strains. Numbers represent MIC values ($\mu\text{g/ml}$). OFX: ofloxacin, NFX: norfloxacin, CPF: ciprofloxacin, SPFX: sparfloxacin, CFX: cefotaxime, MTCN: methicillin, VCMN: vancomycin.

Antibiotics Strains	Quinolones					β -lactams	
	OFX	NFX	CPF	SPFX	CFX	MTCN	VCMN
Ofloxacin susceptible							
<i>S. aureus</i> 285	0.391	1.563	1.563	0.098	3.125	3.125	0.781
<i>S. aureus</i> 503	0.391	1.563	0.781	0.098	0.781	1.563	0.391
Ofloxacin resistant							
<i>S. aureus</i> 179	6.250	50.000	12.500	6.250	6.250	6.250	0.781
<i>S. aureus</i> 241	6.250	50.000	12.500	6.250	12.500	6.250	0.781
<i>S. aureus</i> 293	12.500	50.000	12.500	6.250	25.000	25.000	0.781
<i>S. aureus</i> 303	6.200	50.00	12.500	12.500	6.250	6.250	0.781
<i>S. aureus</i> 1763	25.000>	200.000	12.500	6.250	6.250	0.781	
<i>S. aureus</i> 17740	6.250	50.000	12.500	25.000	12.500	12.500	0.781
<i>S. aureus</i> 17746	12.500	50.000	12.500	6.250	6.250	3.125	0.781
<i>S. aureus</i> 17845	6.250	50.000	12.500	6.250	12.500	6.250	0.781




Fig. 3. Southern analysis of RFLPs of *gyrA* locus of *S. aureus*. Chromosomal DNAs of *S. aureus* was digested with A: *EcoRI*, B: *HindIII*, C: *PstI* and D: *AluI*. In case of *PstI* and *AluI* digestion, figures are drawn according to the autoradiogram because of the weak signal. Lane 1-9: *S. aureus* 179, *S. aureus* 241, *S. aureus* 293, *S. aureus* 303, *S. aureus* 17613, *S. aureus* 17740, *S. aureus* 17746, *S. aureus* 17845, *S. aureus* 8236 (ORSAs), lane 10, 11: *S. aureus* 285, *S. aureus* 503 (OSSAs).




Fig. 4. Identification of amplified product of *gyrA*-290 of *S. aureus*. A: amplified PCR product of *gyrA*-290 from *S. aureus* strains. M: λ BstEII, I: *S. aureus* 285, II: *S. aureus* 17613; B, I: digestion of PCR product from *S. aureus* 285 with 1: *HpaII*, 2: *SnaBI*, 3: *AccI*, II: digestion of PCR product from *S. aureus* 17613 with 1: *HpaII*, 2: *SnaBI*, 3: *AccI*.

was weak in general probably because of the low homology (60%) between *E. coli* and *S. aureus* (14).

6 kb band was found with *EcoRI* digestion both in ORSAs and OSSAs (Fig 3A). With *HindIII* digestion, 6.5 kb band appeared in ORSAs but none in OSSAs (Fig 3B). With *PstI* digestion, *S. aureus* 179 showed unique >23 kb band as well as <23 kb band present in all 10 *S. aureus* strains (Fig. 3C). A high molecular weight band (>23 kb) was found with *BamHI* and with *BglII* both in ORSAs and OSSAs (data not shown). However it was difficult to size the fragments and to judge the possible size polymorphism because the fragments were too big to be analyzed accurately with the 0.8% agarose gel system.

Seven 4-cutter enzymes, *AluI*, *MboI*, *HhaI*, *RsaI*, *CfoI*, *HpaII* and *TaqI*, were also used. However with the exception of *AluI*, no band was detected with 2 week exposure time (data not shown). In




Fig. 5. DNA sequence comparison of ofloxacin susceptible and resistant *S. aureus*. The sequence of *S. aureus* 81231 was reported previously (8).

case of *AluI*, *S. aureus* 179 and 241 showed 1.9 kb band and *S. aureus* 17740, 17746, 17845 and 8236 showed 2.2 kb band (Fig 3D). Among 2 OSSA strains, strain 285 showed 2.2 kb band and strain 503 showed 2.3 kb band.

Therefore RFLPs between ORSAs and OSSAs were detected with *HindIII*, *PstI* and *AluI* digestions.

Sequence Comparison of *gyrA*-290

The 290 bp region of *gyrA* of ORSAs and

OSSAs between amino acid 26 and 121 was amplified by PCR (Fig 4A). The amplified products were digested with *Hpa*II, *Sna*BI and *Acc*I (Fig 4B). The sizes of digestion products were the same as those could be predicted by the published *S. aureus* sequence (8).

The sequence comparison of ORSA and OSSA demonstrated two base difference with 290 bp region (Fig 5). A point mutation of C to T at the second base of amino acid 84 resulting Ser to Leu substitution was observed in all ORSA strains. Another base change, C to T, resulting no amino acid change was observed in the third base of amino acid 86 in all ORSA strains. Also the sequence of *gyrA*-290 of OSSAs was compared to that of published sequence of *S. aureus* of that region. A single base change resulting silent mutation was revealed in the third base of amino acid 86.

DISCUSSIONS

OSSAs were highly susceptible to quinolones and vancomycin and moderately susceptible to cefotaxime and methicillin. However MIC test result of clinical isolates of eight ORSA strains revealed that ORSAs were resistant not only to quinolones but also, even though with lesser degree, to cefotaxime and methicillin. Only vancomycin was equally effective against OSSAs and ORSAs. The antibiotic spectra of ORSA strains were similar to each other in general. However strain 17613 draws attention in that the degree of resistance against hydrophilic quinolones was most high among nine ORSAs. Sparfloxacin proved to be the most efficient agent against OSSAs among seven antibiotics used in this study. The potent antibacterial activity of sparfloxacin might be related to its lipophilicity which facilitates its permeation. The fact that the resistance was most severely developed against sparfloxacin (up to 250 fold increase of MIC) in *S. aureus* in our study is surprising because sparfloxacin is one of the newest quinolones and its usage in the treatment of *S. aureus* infections seems to increase. Further studies seem to be necessary to understand the frequency and degree of sparfloxacin resistance development in *S. aureus*.

We searched possible RFLPs first in order to group ORSAs and secondly to find mutation(s) between OSSAs and ORSAs. *E. coli gyrA* probe was homologous enough to allow us examine RFLPs in *S. aureus gyrA* locus with six cutter enzymes. However not much information was obtained with four cutter enzymes which were expected to reveal more length polymorphism. It may not be surprising that we failed to detect *S. aureus gyrA* gene fragments probing *E. coli gyrA* with many four cutters except *Alu*I because the

sequence homology between *E. coli* and *S. aureus gyrA* genes was relatively low and the possibility to contain homologous region(s) within the shortened fragments became even lower. *Pst*I and *Alu*I digestions presented some possibilities of sequence variation(s) in the *gyrA* locus of ORSAs. However it is insufficient to know whether those sequence variations are within and/or outside the *gyrA* gene and are expressed as real amino acid changes with the limited RFLP informations.

Sequencing the entire *gyrA* genes of each *S. aureus* strain would be able to answer above questions. However that is not a simple task. Therefore we decided to examine 290 bp region which contains N-terminal amino acid residues 26 to 121 of gyrase A. A single point mutation at the second base of amino acid 84 which resulted an amino acid change Ser to Leu was found in every ORSA strains sequenced. The possibility that all ORSA isolates is the same strain should be excluded because differences were observed in RFLPs and in their antibiotic spectra even though we can not completely exclude the possibility that some of them might be the same origin. Mutations of *E. coli gyrA* gene were observed in Ala-67, Ser-83 and Gln-106 in quinolone resistant strains (12, 19, 20). The amino acids in these three amino acids are all conserved in *S. aureus*. Studies in *E. coli* indicate mutations were most frequently found in Ser-83 of *gyrA*. These suggest the possible involvement of Ser-84 residue of gyrase A in quinolone-gyrase interaction and thereby quinolone resistance development.

In this study only *gyrA* was examined in ORSA strains. Other possibilities such as mutations in *gyrB* and changes in permeabilities and in efflux systems involving *norA* gene (17, 21) need to be studied.

ACKNOWLEDGEMENTS

This work was supported by the Korea Science and Engineering Foundation research grant #923-0400-009-1. We wish to thank seungyong Park for techniques of PCR and Jaeman Kim of Genetic Engineering Research Institute for helpful advices in the procedures of cloning.

REFERENCES

1. Cohen, S.P., D.C. Hooper, J.S. Wolfson, and S.B. Levy, 1988. Endogenous active efflux of norfloxacin in susceptible *Escherichia coli*. *Nucl. Acids Res.*, **32**, 1187-1191.
2. Cullen, M.E., A.W. Wyke, R. Kuroda, and L.M. Fisher, 1989. Cloning and characterization of a DNA gyrase A gene from *Escherichia coli* that confers clinical resistance to 4-quinolones. *Antimicrob. Agents Chemother.*, **33**, 886-

- 894.
3. Daum, T.E., D.R. Schaberg, M.S. Terpenning, W. S. Sottile, and C.A. Kauffman, 1990. Increasing resistance of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.*, **34**, 1862-1863.
 4. Gellert, M., 1981. DNA topoisomerases. *Annu. Rev. Biochem.*, **50**, 879-910.
 5. Hirai, K., H. Aoyama, T. Irikura, and S. Mitsuhashi, 1986. Differences in susceptibility to quinolones of outer membrane mutants of *Salmonella typhimurium* and *Escherichia coli*. *Antimicrob. Agents Chemother.*, **29**, 535-538.
 6. Hirai, K., H. Aoyama, S. Suzue, and S. Mitsuhashi, 1986. Isolation and characterization of norfloxacin-resistant mutants of *Escherichia coli* K-12. *Antimicrob. Agents Chemother.*, **30**, 248-253.
 7. Hooper, D.C., J.S. Wolfson, K.S. Souza, C. Tung, and M.N. Swartz, 1986. Genetics and biochemical characterization of norfloxacin resistance in *Escherichia coli*. *Antimicrob. Agents Chemother.*, **29**, 639-644.
 8. Hopewell, R., M. Oram, R. Briesewitz, and L.M. Fisher, 1990. DNA cloning and organization of the *Staphylococcus aureus* *gyrA* and *gyrB* genes: Close homology among gyrase proteins and implications for 4-quinolone action and resistance. *J. Bacteriol.*, **172**, 3481-3484.
 9. Karl, D. and R.J. Franco, 1988. Inhibitors of DNA topoisomerases. *Biochemistry*, **27**, 7.
 10. Kirchhausen, T., J.C. Wang and S.C. Harrison, 1985. DNA gyrase and its complexes with DNA: Direct observation by electron microscopy. *Cell*, **41**, 933-943.
 11. Menzel, R. and M. Gellert, 1987. Modulation of transcription by DNA supercoiling: A deletion analysis of the *Escherichia coli* *gyrA* and *gyrB* promoters. *Proc. Natl. Acad. Sci. USA* **88**, 4185-4189.
 12. Oram, M., and L.M. Fisher, 1991. 4-quinolone resistance mutations in the DNA gyrase of *Escherichia coli* clinical isolates identified by using the polymerase chain reaction. *Antimicrob. Agents Chemother.*, **35**, 387-389.
 13. Piercy, E.A., D. Barbaro, J.P. Luby, and P.A. Mackowiak, 1989. Ciprofloxacin for methicillin-resistant *S. aureus* infections. *Antimicrob. Agents Chemother.*, **33**, 128-130.
 14. Sreedharan, S., M. Oram, B. Jensen, L.R. Peterson and L.M. Fisher, 1990. DNA gyrase *gyrA* mutations in ciprofloxacin-resistant strains of *Staphylococcus aureus*: Close similarity with quinolone resistance mutations in *Escherichia coli*. *J. Bacteriol.*, **172**, 7260-7262.
 15. Sugino, A., N.P. Higgins, and Cozzarelli, 1980. DNA gyrase subunit stoichiometry and the covalent attachment of subunit A to DNA during DNA cleavage. *Nucl. Acids Res.*, **8**, 3865-3874.
 16. Swanberg, S.L. and J.C. Wang, 1987. Cloning and sequencing of the *Escherichia coli* *gyrA* gene coding for the A subunit DNA gyrase. *Mol. Biol.*, **197**, 729-736.
 17. Ubukata, K., N.I. Yamashita and M. Konno, 1989. Cloning and expression of *norA* gene for fluoroquinolone resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.*, **33**, 1535-1539.
 18. Wolfson, J.S. and D.C. Hooper. *Quinolones*; J.R. Prous Science Publishers: Barcelona, Spain 1989.
 19. Yoshida, H., T. Kojima, J. Yamagishi and Nakamura, 1988. Quinolone-resistant mutations of the *gyrA* gene of *Escherichia coli*. *Mol. Gen. Genet.*, **211**, 1-7.
 20. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura, 1990. Quinolone resistance-determining region in the DNA *gyrA* gene of *Escherichia coli*. *Antimicrob. Agents Chemother.*, **34**, 1271-1272.
 21. Yoshida, H., M. Bogaki, and S. Nakamura, 1990. Proportion of DNA gyrase mutants among quinolone-resistant strains of *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.*, **34**, 1273-1275.

(Received July 31, 1992)

(Accepted August 17, 1992)

초 록: *Staphylococcus aureus*에서의 Quinolone 내성 기작에 관한 연구

이윤경·공재양·이영하¹·김은희²(한국화학연구소 의약품성실, ¹충남대학교 미생물학과, ²배재대학교 유전공학과)

*Staphylococcus aureus*의 퀴놀론계 약물에 대한 내성 기작을 이해하고자 ofloxacin 에 내성을 보이는 임상 채취 8 균주의 *Staphylococcus aureus* (ORSA)에 대하여 MIC 검사, *gyrA* 유전자 부근의 Southern 분석 및 아미노산 26번에서 121번까지를 포함하는 290 bp의 *gyrA* 유전자 일부(*gyrA*-290)의 염기 서열 분석을 행하였다. ORSA 들은 퀴놀론계 약물에 대하여 높은 수준의 내성을 보였으며(8-250 배의 MIC 증가), β -lactam계 약물에 대하여도 상당한 수준의 내성(2-32 배의 MIC 증가)을 보였다. 하지만 ORSA 들은 vancomycin 에 관한 감수성의 변화를 보이지는 않았다. ORSA 에 대하여 Southern 분석을 실시한 결과, *Hind*III, *Pst*I 및 *Alu*I의 경우에는 *gyrA* 유전자 부근에서 RFLP 가 발견되었다. *GyrA* 유전자를 더 분석하고자 *gyrA*-290 부분을 중합효소 연쇄반응(PCR)으로 증폭하여 pTZ 벡터에 클론하였다. *gyrA*-290 의 염기 서열을 분석한 결과, 8 ORSA 균주 모두에 관하여 점 돌연변이의 결과로 Ser-84 이 Leu-84 으로 치환됨이 밝혀졌다. 이로써 *gyrA* 유전자의 84 번째 아미노산의 치환이 *Staphylococcus aureus*의 퀴놀론 내성 발현의 주요한 기작 중 하나인 것으로 나타났다.